While individual results vary, GLP-1 medications have been studied for their ability to: Help regulate blood sugar levels Influence appetite regulation Support sustained lifestyle changes For instance, a 68-week clinical trial found that participants taking semaglutide along with lifestyle intervention had significantly greater improvements compared to placebo
1 In the REIMAGINE 2 trial, the most commonly reported AEs were GI-related, occurring in 405/603 (67.2%) participants in the CagriSema 2.4 mg/2.4 mg group, 326/605 (53.9%) participants in the semaglutide 2.4 mg group, 60/152 (39.5%) participants in the cagrilintide 2.4 mg group, 329/594 (55.4%) participants in the CagriSema 1 mg/1 mg group, 288/608 (47.4%) participants in the semaglutide 1 mg group, and 42/149 (28.2%) participants in the placebo group
Giving up smoking, which is believed to encourage symptoms by relaxing the lower oesophageal sphincter
But your actual target should come from a personalized calculation
By offering a cheaper alternative, Lilly is pushing back against a massive and growing market of alternative weight-loss drugs